Your session is about to expire
← Back to Search
Interleukin 17A Inhibitor
Izokibep for Hidradenitis Suppurativa
Phase 2
Waitlist Available
Research Sponsored by ACELYRIN Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Hidradenitis suppurativa lesions present in ≥ 2 distinct anatomic areas , one of which is Hurley Stage II or III.
18 years to 75 years of age
Must not have
Uncontrolled, clinically significant system disease
Malignancy within 5 years.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up part b period 1: screening (day -28) to follow-up (week 39)
Summary
This trial is testing Izokibep, a drug that blocks inflammation-causing proteins, in adults with moderate to severe hidradenitis suppurativa. The drug aims to reduce inflammation by targeting the IL-17A protein.
Who is the study for?
Adults aged 18-75 with moderate to severe Hidradenitis Suppurativa (HS), having lesions in at least two areas, one being Hurley Stage II or III. Participants must have had HS for over a year, not responded well to oral antibiotics, and be willing to use daily antiseptics and keep a pain diary.
What is being tested?
The trial is testing Izokibep, an inhibitor targeting interleukin 17A (IL-17A) against a placebo. It aims to assess the drug's effectiveness and safety when injected under the skin in those with HS who haven't seen improvement from standard treatments.
What are the potential side effects?
While specific side effects of Izokibep are not listed here, inhibitors like it can potentially cause injection site reactions, increased risk of infections due to immune system suppression, allergic reactions, or other immune-related conditions.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I have skin lesions in 2 different areas, with at least one being moderate to severe.
Select...
I am between 18 and 75 years old.
Select...
I have skin lesions in 2 different areas, with at least one area being moderate to severe.
Select...
I agree to use daily skin cleaning products.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I do not have any uncontrolled serious illnesses.
Select...
I was diagnosed with cancer within the last 5 years.
Select...
I do not have any skin conditions that could affect the study.
Select...
I do not have an active infection or a history of serious infections.
Select...
I have been diagnosed with HIV.
Select...
I have a history of diseases that affect the protective covering of nerves.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ part b period 1: screening (day -28) to follow-up (week 39)
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~part b period 1: screening (day -28) to follow-up (week 39)
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Part A: Hidradenitis Suppurativa Clinical Response (HiSCR75)
Part B: Hidradenitis Suppurativa Clinical Response 75 (HiSCR75)
Secondary study objectives
Part B Period 1: Incidence of Treatment-emergent Adverse Events (TEAEs) Leading to Discontinuation
Part B Period 1: Incidence of Treatment-emergent Adverse Events (TEAEs) of Special Interest
Part B: Participants Achieving HiSCR100
+5 moreSide effects data
From 2024 Phase 2 trial • 205 Patients • NCT0535580554%
Injection site erythema
28%
Injection site pruritus
16%
Nasopharyngitis
16%
Injection site swelling
14%
Headache
9%
Upper respiratory tract infection
5%
Oropharyngeal pain
5%
Back pain
5%
Injection site pain
4%
Injection site inflammation
4%
Nausea
4%
Injection site oedema
4%
Influenza
4%
Urinary tract infection
4%
Viral upper respiratory tract infection
2%
Thermal burn
2%
Muscle spasms
2%
Toothache
2%
Migraine
2%
Arthritis
2%
Dysmenorrhoea
2%
Skin papilloma
2%
Diarrhoea
2%
Groin pain
2%
Tonsillitis
2%
Injection site urticaria
2%
Injection site irritation
2%
Asthenia
2%
Epstein-Barr virus infection
2%
Axillary pain
2%
Herpes simplex
2%
Cutaneous vasculitis
2%
Pyrexia
2%
Eczema
2%
Fall
2%
Fatigue
2%
Injection site discolouration
2%
Erythema nodosum
2%
Tooth disorder
2%
Hot flush
2%
Amenorrhoea
2%
COVID-19
2%
Abdominal discomfort
2%
Arthralgia
2%
Tinea pedis
2%
Orthostatic hypotension
2%
Gastroenteritis viral
2%
Injection site hypersensitivity
2%
Gastrointestinal viral infection
2%
Tonsillitis bacterial
2%
Dizziness
2%
Joint dislocation
2%
Conjunctivitis allergic
2%
Injection site warmth
2%
Intertrigo
2%
Acute kidney injury
2%
Bradycardia
2%
Autoimmune thyroiditis
2%
Proteinuria
2%
SARS-CoV-2 test positive
2%
Alanine aminotransferase increased
2%
Tooth fracture
2%
Conjunctival haemorrhage
2%
Foot fracture
2%
Postoperative wound infection
2%
Urticaria
2%
Injection site reaction
2%
Injection site bruising
100%
80%
60%
40%
20%
0%
Study treatment Arm
Part B Izokibep 160 mg QW - Period 1
Part B Izokibep 160 mg Q2W - Period 1
Part A Izokibep 160 mg QW
Part B Placebo QW/Q2W - Period 1
Trial Design
5Treatment groups
Experimental Treatment
Placebo Group
Group I: Part B (Double-blind) izokibep every weekExperimental Treatment1 Intervention
Participants will receive izokibep every week for 31 weeks.
Group II: Part B (Double-blind) izokibep every other weekExperimental Treatment1 Intervention
Participants will receive izokibep every other week for 30 weeks.
Group III: Part A (Open-label) izokibep every weekExperimental Treatment1 Intervention
Participants will receive izokibep every week from Day 1 through Week 31
Group IV: Part B (Double-blind) placebo every other weekPlacebo Group1 Intervention
Participants will receive placebo every other week up to Week 14, then izokibep from Week 16 to Week 30.
Group V: Part B (Double-blind) placebo every weekPlacebo Group1 Intervention
Participants will receive placebo every week up to Week 15, then izokibep from Week 16 to Week 31.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Izokibep
2022
Completed Phase 2
~220
Research Highlights
Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Hidradenitis Suppurativa (HS) treatments often target inflammatory pathways to reduce symptoms and prevent flare-ups. Izokibep, a selective inhibitor of interleukin 17A (IL-17A), works by blocking this specific cytokine, which plays a crucial role in the inflammatory process of HS.
By inhibiting IL-17A, Izokibep can potentially reduce the chronic inflammation and lesions characteristic of HS. Other treatments, such as TNF-alpha inhibitors (e.g., infliximab) and IL-23 inhibitors, also target specific cytokines involved in the inflammatory response.
These treatments are significant for HS patients as they directly address the underlying inflammation, offering relief from pain, reducing the frequency of flare-ups, and improving the overall quality of life.
[Hidradenitis suppurativa. Response to treatment with infliximab].
[Hidradenitis suppurativa. Response to treatment with infliximab].
Find a Location
Who is running the clinical trial?
ACELYRIN Inc.Lead Sponsor
8 Previous Clinical Trials
902 Total Patients Enrolled
1 Trials studying Hidradenitis Suppurativa
258 Patients Enrolled for Hidradenitis Suppurativa
Donald Betah, MDStudy DirectorACELYRIN Inc.
1 Previous Clinical Trials
7 Total Patients Enrolled
Paul M Peloso, MD, MSc.Study DirectorACELYRIN Inc.
1 Previous Clinical Trials
96 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I had outpatient surgery within the last 8 weeks or inpatient surgery within the last 12 weeks.I have been diagnosed with HIV.I have been diagnosed with hidradenitis suppurativa for at least 1 year.I do not have active tuberculosis or fungal infection, or it has been treated and resolved.I do not have any skin conditions that could affect the study.I do not have an active infection or a history of serious infections.I am willing to keep a daily diary of my skin pain.I have skin lesions in 2 different areas, with at least one being moderate to severe.You have provided informed consent to comply with the requirements and restrictions listed in the ICF and in this protocol.It seems like this criterion is not specific. Could you please provide more details or context so that I can assist you accurately?I have been diagnosed with hidradenitis suppurativa for at least 1 year.I do not have any uncontrolled serious illnesses.I have chronic pain not related to my skin condition.I am between 18 and 75 years old.I have skin lesions in 2 different areas, with at least one area being moderate to severe.My condition matches the specific type and characteristics required.I was diagnosed with cancer within the last 5 years.You have three or more abscesses and inflammatory nodules at the screening and enrollment.You have more than 20 draining fistulas.You have five or more abscesses or inflammatory nodules at the time of screening and before starting the study.I have a history of diseases that affect the protective covering of nerves.I agree to use daily skin cleaning products.You are in danger of hurting yourself or others.My skin condition didn't improve with oral antibiotics, or it came back after stopping them, or I can't take them due to side effects or other reasons.
Research Study Groups:
This trial has the following groups:- Group 1: Part B (Double-blind) izokibep every other week
- Group 2: Part B (Double-blind) placebo every other week
- Group 3: Part B (Double-blind) izokibep every week
- Group 4: Part A (Open-label) izokibep every week
- Group 5: Part B (Double-blind) placebo every week
Awards:
This trial has 0 awards, including:Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Hidradenitis Suppurativa Patient Testimony for trial: Trial Name: NCT05355805 — Phase 2